The listing status of Apelvis in China in 2024 and the latest information on medical insurance

In recent years, the targeted therapeutic drug Alpelisib (Alpelisib) has attracted much attention worldwide. Its remarkable effect in the treatment of PIK3CA mutated breast cancer has brought new hope to patients. However, for Chinese breast cancer patients, the marketing and medical insurance situation of Apelvis is a matter of concern.

Currently, Apelvis is still missing from the Chinese market as it has not yet been approved by the China Food and Drug Administration and put on the market. The drugs covered by the medical insurance system are all drugs marketed in China, so Apelvis is not included in the Chinese Medical Insurance Drug List. This means that patients who need Apelvis treatment cannot enjoy the benefits of medical insurance reimbursement in China, which increases the financial burden and difficulty of treatment for patients.

For patients in need of medication, Apelvis can currently only be purchased through formal overseas channels. There are two main versions on the market. One is the European version of the original drug produced by Novartis in Switzerland. The specification is 150mg*56 tablets and the price is about more than 40,000 yuan. The other is the Indian original research version, with a specification of 150mg*28 tablets, and the price is relatively affordable, about 5,000 yuan. The original drugs are completely consistent in ingredients and effects, and the price difference is only due to different medical policies in different countries.

Although the efficacy of the original drug has been widely recognized, its high price is still unaffordable for some patients. In order to solve this problem, some generic drugs have gradually entered the market, providing patients with new treatment options. In Laos, the generic version of Apelvis produced by Lucius sells for about more than 2,000 yuan per box, with a specification of 150mg*28 tablets. This price is much lower than the original drug, which greatly reduces the treatment costs for patients.

It should be noted that patients should choose formal channels when purchasing and using Apelvis to ensure the quality and safety of the drug. At the same time, patients should use drugs rationally under the guidance of doctors and follow requirements such as dosage and medication cycle to ensure maximum treatment effects.

In short, the marketing and medical insurance situation of Apelvis in China still requires attention. For patients in need of medicines, purchasing medicines through formal overseas channels is currently the only option.